Christoph is a partner at Third Rock Ventures where he has been instrumental in founding and launching several life science companies including Blueprint Medicines (BPMC), Relay Therapeutics (RLAY), Thrive Earlier Detection (now part of EXAS), Celsius Therapeutics, and MOMA Therapeutics. He currently serves as the chief scientific officer at MOMA Therapeutics as well as the head of R&D strategy at Thrive – an Exact Sciences Company. Christoph has contributed to the discovery and development of eight FDA-approved cancer medicines.

Christoph studied human genetics in Salzburg, Austria and got his PhD in biology from the University of Heidelberg, Germany. He received his MBA with a focus on medical services management from the Johns Hopkins Carey Business School in Baltimore, MD.